A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: Study design and rationale of the 'MAGIC cell-5-combination cytokine trial'
Trials, ISSN: 1745-6215, Vol: 12, Issue: 1, Page: 33
2011
- 10Citations
- 37Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes8
- CrossRef8
- Policy Citations2
- Policy Citation2
- Captures37
- Readers37
- 37
Article Description
Background: Bone marrow derived stem/progenitor cell transplantation after acute myocardial infarction is safe and effective for improving left ventricular systolic function. However, the improvement of left ventricular systolic function is limited. This study will evaluate novel stem/progenitor cell therapy with combination cytokine treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulating factor (G-CSF) in patients with acute myocardial infarction.Methods: The 'MAGIC Cell-5-Combination Cytokine Trial' is a multicenter, prospective, randomized, 3-arm, controlled trial with blind evaluation of the endpoints. A total of 116 patients will randomly receive one of the following three treatments: an intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G-CSF (n = 58), an intracoronary infusion of peripheral blood stem cells mobilized with G-CSF alone (n = 29), or conventional therapy (n = 29) at phase I. Patients with left ventricular ejection fraction < 45% at 6 months, in the patients who received stem cell therapy at phase I, will receive repeated cell therapy at phase II. The objectives of this study are to evaluate the safety and efficacy of combination cytokine therapy with erythropoietin and G-CSF (phase I) and repeated progenitor/stem cell treatment (phase II).Discussion: This is the first study to evaluate the safety and efficacy of combination cytokine based progenitor/stem cell treatment.Trial registration: http://www.ClinicalTrials.gov identifier: NCT00501917. © 2011 Kang et al; licensee BioMed Central Ltd.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79551631891&origin=inward; http://dx.doi.org/10.1186/1745-6215-12-33; http://www.ncbi.nlm.nih.gov/pubmed/21299845; https://clinicaltrials.gov/ct2/show/NCT00501917; https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-12-33; https://dx.doi.org/10.1186/1745-6215-12-33; https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/1745-6215-12-33; http://www.trialsjournal.com/content/12/1/33; http://link.springer.com/article/10.1186/1745-6215-12-33/fulltext.html; https://link.springer.com/track/pdf/10.1186/1745-6215-12-33; https://link.springer.com/articles/10.1186/1745-6215-12-33; https://link.springer.com/article/10.1186/1745-6215-12-33; http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-12-33
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know